NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

NervGen Pharma Corp. (NGEN) Stock Analysis

NervGen Pharma Corp. (NGEN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NGEN

$1.50

−$0.04 (−2.60%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NGEN with… →

NGEN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.54
Previous Close
$1.54
Day's Range
1.50–1.55
52-Week Range
1.50–6.30
Volume
293.46K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.82
Valuation
Market Cap
$161.28M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.57
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$44.12M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
107.52M
1-Year Return
−48.81%
Dividend and dates
Earnings Date
November 23, 2026estimated
Avg Volume
497.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NGEN closed at $1.50, −48.81% over 1 year.

NervGen Pharma Corp. (NGEN) has a market capitalization of $161.28M.

In fiscal 2025, NGEN reported revenue of $0.00.

NGEN Stock Return by Calendar Year

NervGen Pharma Corp. (NGEN) return since Apr 2019: what $10,000 became

1 year
$10,000 $5,119
−48.81%
5 years
$10,000 $6,977
−30.23%
Since Apr 2019
$10,000 $11,530
+15.30%

If you had invested $10,000 in NervGen Pharma Corp. (NGEN) at the close on April 3, 2019, the earliest close on record here, it would have been worth $11,530 at the close on October 21, 2026: +15.30% in total, +1.90% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−73.21%
2025+156.88%
2024+6.86%
2023+71.43%
2022−44.13%
2021+22.41%
2020+10.13%
2019 (partial year)+21.45%

As of October 21, 2026.

NGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$44.12M—
2024$0.00−$24.25M—
2023$0.00−$22.38M—
2022$0.00−$20.72M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$25.08M−$44.12M—
2024$0.00—−$25.18M−$24.25M—
2023$0.00—−$17.78M−$22.38M—
2022$0.00—−$23.03M−$20.72M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values NervGen Pharma Corp. (NGEN) at $161.28M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 9.

Over the past 52 weeks the price has ranged from $1.50 to $6.30. The most recent close on file for NGEN is $1.50, dated October 21, 2026. That is −$0.04 (−2.60%) against the previous close.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $44.12M. Trailing earnings per share are −0.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.82. Daily returns over the trailing 7 years annualize to a volatility of 76.81%. Over the trailing twelve months the total return is −48.81%. Across 5 years the annualized return works out at −6.95%.

Growth & Income

No dividend is on file for NGEN.

The strongest complete calendar year on file is 2025 at +156.88%; the weakest is 2022 at −44.13%. Of the 6 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is −73.21% year to date.

Peer Comparison

NervGen Pharma Corp. (NGEN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NervGen Pharma Corp. NGEN $161.28M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NervGen Pharma Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NervGen Pharma Corp.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Visit website →